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ZFP36L1 is a member of a family of CCCH tandem zinc ﬁnger proteins (TTP family) able to bind to AU-rich elements in
the 3-untranslated region of mRNAs, thereby triggering their degradation. The present study suggests that such
mechanism is used during hematopoiesis to regulate differentiation by posttranscriptionally modulating the expression
of speciﬁc target genes. In particular, it demonstrates that ZFP36L1 negatively regulates erythroid differentiation by
directly binding the 3 untranslated region of Stat5b encoding mRNA. Stat5b down-regulation obtained by ZFP36L1
overexpression results, in human hematopoietic progenitors, in a drastic decrease of erythroid colonies formation. These
observations have been conﬁrmed by silencing experiments targeting Stat5b and by treating hematopoietic stem/
progenitor cells with drugs able to induce ZFP36L1 expression. Moreover, this study shows that different members of
ZFP36L1 family act redundantly, because cooverexpression of ZFP36L1 and family member ZFP36 determines a cumu-
lative effect on Stat5b down-regulation. This work describes a mechanism underlying ZFP36L1 capability to regulate
hematopoietic differentiation and suggests a new target for the therapy of hematopoietic diseases involving Stat5b/JAK2
pathway, such as chronic myeloproliferative disorders.
INTRODUCTION
The TTP family of tandem zinc ﬁnger proteins includes
TTP/ZFP36, TIS11b/ZFP36L1, and TIS11d/ZFP36L2, all of
which have been shown to directly bind AU-rich elements
(ARE) and promote degradation of the host transcript
(Carballo et al., 2000; Ogilvie et al., 2005). Their central
RNA-binding domain interacts with AU-rich elements
(UUAUUUAUU), whereas the N- and C-terminal domains
recruit enzymes involved in the mRNA degradation path-
way. Expression of all TTP family genes can be induced by
phorbol esters (TPA) and various other mitogenic stimuli,
such as growth factors, in a broad variety of cell types
(Gomperts et al., 1992; Corps and Brown, 1995). For ZFP36
and in part also for other members, binding to and destabi-
lization of TNF-, granulocyte macrophage colony-stimulat-
ing factor (GM-CSF), and Vegf mRNAs has been demon-
strated (Carballo et al., 1998, 2000; Lai et al., 1999; Ciais et al.,
2004). Furthermore, ZFP36 is a transcriptional regulator
(Murata et al., 2000, 2002) and mitogens induce its rapid
nuclear to cytosolic translocation (Taylor et al., 1996). Recent
publications suggest that TTP family proteins are phosphor-
ylated (Taylor et al., 1995), might be targets of the p38 MAPK
pathway (Carballo et al., 2001; Mahtani et al., 2001), and
might be involved in the regulation of apoptosis (Johnson et
al., 2000; Johnson and Blackwell, 2002). Finally, TTP family
members have recently been involved in cell differentiation
and cancer. In particular, ZFP36 has been indicated as a
critical regulator of dendritic cells maturation (Emmons et
al., 2008), and it has been demonstrated that targeted dis-
ruption of ZFP36L2 results in defective hematopoiesis
(Stumpo et al., 2009) and that ZFP36 is suppressed in many
cancers, altering tumorigenic phenotypes and patient prog-
nosis (Brennan et al., 2009).
The Stat5/JAK2 pathway is widely studied. Its aberrant
activation is involved in several diseases (Benekli et al., 2003;
Choudhary et al., 2007; Kotecha et al., 2008; Wagner and Rui,
2008; Funakoshi-Tago et al., 2009), and particularly its con-
stitutive activation dependent on JAK2 V617F mutation un-
derlies chronic myeloproliferative disorders (Kralovics et al.,
2005; Heller et al., 2006; Guglielmelli et al., 2007; Levine and
Gilliland, 2008; Grimwade et al., 2009). Conversely, the same
pathway is also involved in the control of normal hemato-
poiesis, because it plays a fundamental role during erythroid
maturation (Grebien et al., 2008; Olthof et al., 2008). The
Stat5a and Stat5b genes belong to the signal transducer and
activator of transcription (Stat) family of transcription fac-
tors. The family of Stat genes is believed to originate from
successive genome duplication and functional divergence of
a single ancestral Stat gene early in vertebrate evolution. A
recent duplication of Stat5 is believed to have given rise to
the closely related Stat5a and Stat5b homologous genes that
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3340encode proteins that in humans are 91% identical, the
main difference between the two proteins residing in a ﬁve-
amino acid insertion at the COOH-terminus of Stat5b (Crispi
et al., 2004). Stat5a and Stat5b exert redundant yet distinct
functions (Basham et al., 2008) both in physiological and
pathological conditions; for instance Stat5b and not Stat5a is
responsible for inducing an increase of cell motility and
invasiveness in hepatocellular carcinoma (Lee et al., 2006).
The common aspects and the differences between Stat5a and
Stat5b’s behavior depend on multiple factors such as differ-
ences in mRNA levels (Ambrosio et al., 2002), activation by
phosphorylation (Moucadel and Constantinescu, 2005), or as
we point out in the present work, a different pattern of tissue
speciﬁc expression.
The present study has its starting point in the analysis of
a gene expression proﬁle of human hematopoietic cell pop-
ulations (data not shown) that consistently shows that
ZFP36L1 expression is substantially low in erythroid pro-
genitors compared with the other hematopoietic cell types.
On these premises, the role of ZFP36L1 was evaluated by
ectopic expression and gene silencing experiments in human
hematopoietic cord blood–derived CD34 stem/progenitor
cells and on the erythroleukemia cell line carrying the JAK2
V617F mutation, Hel. Such experiments conﬁrmed that
ZFP36L1 expression negatively regulates erythroid matura-
tion, and the results were further validated by monitoring
the effect of cinnamon-derived polyphenols, a drug able to
induce the expression of TTP gene family (Schoene et al.,
2005; Cao et al., 2007), on the same cell populations. To
investigate the mechanisms underlying such biological be-
havior, we hypothesized that ZFP36L1 might interfere with
Stat5/JAK2 pathway, whose activity is pivotal for erythroid
differentiation and survival. We demonstrated that ZFP36L1
and also ZFP36 are able to directly bind the 3-untranslated
region of Stat5b mRNA, thereby triggering its degradation.
As conﬁrmed by gene silencing experiments targeting
Stat5b, its down-regulation is sufﬁcient to inhibit the forma-
tion of erythroid precursors from CD34 human stem/
progenitor cells. Moreover, the current study demonstrates
that at least two members of the TTP family, ZFP36L1 and
ZFP36, are capable of acting redundantly, because their
common overexpression results in a cumulative effect on
Stat5b down-regulation.
MATERIALS AND METHODS
Cell Cultures and Treatments
The U937 cell line was obtained from ATCC (Rockville, MD) and cultured
in RPMI1640 medium (Euroclone, Devon, United Kingdom), supple-
mented with 10% heat-inactivated fetal bovine serum (Biowhittaker, Walk-
ersville, MD) and 1 mM l-glutamine (Euroclone). The Hel cell line was
obtained from ATCC and was cultured in IMDM medium (Euroclone) sup-
plemented with 10% heat-inactivated fetal bovine serum and 1 mM l-glu-
tamine. GPenvAm12 cells and human embryonic kidney (HEK) 293 cells
were cultured in DMEM (Euroclone), supplemented with 10% heat-inacti-
vated fetal bovine serum and 1 mM l-glutamine. Ecotropic Phoenix cells were
cultured in IMDM medium supplemented with 10% heat-inactivated fetal
bovine serum and 1 mM l-glutamine.
Human CD34 hematopoietic stem/progenitor cells (HSCs) were puriﬁed
from umbilical cord blood (CB) samples as already described (Piacibello et al.,
1998; Montanari et al., 2005) and seeded (5–10  104/ml) in IMDM (Euroclone)
containing 20% heat-inactivated fetal bovine serum and early acting human
hematopoietic cytokines: 50 ng/ml stem cell factor (SCF) and Flt3-ligand (Flt3-l),
and 10 ng/ml interleukin-6 (IL-6) and interleukin-3 (IL-3; R&D Systems, Minne-
apolis, MN). These experimental conditions normally promote a mixed granulo-
monocyte differentiation of CD34 cells that is generally achieved within 14 d
from plating (Piacibello et al., 1998; Montanari et al., 2005).
For CFC assay CD34 cells were cultured for 48 h before transfection with
nontargeting control siRNA/anti-Stat5b siRNAs or before infection with viral
supernatants; cells were then plated as already described in a complete
methylcellulose medium (MethoCult H4434, Stem Cell Technologies,Vancou-
ver, BC, Canada) between 24 and 48 h after transfection or 24 h after puriﬁ-
cation of transduced cells. Colonies were scored 14 d after plating as erythroid
(burst forming unit-erythroid [BFU-E]  colony forming unit-erythroid [CFU-
E]), CFU-GEMM, CFU-GM, CFU-G, or CFU-M. Error bars represent SEM
calculated on a set of three to four independent experiments (*p  0.05).
Human primary myeloblasts, monoblasts, erythroblasts, and megakaryo-
blasts were generated by in vitro culture of cord blood CD34 HSCs per-
formed as already described (Gemelli et al., 2008).
Cinnamon extracts were kindly provided by Dr. R. A. Anderson (Human
Nutrition Research Center, Beltsville, MD); they were resuspended in water
and added once to IMDM culture medium/methylcellulose medium at the
concentrations indicated in ﬁgure legends, and medium was not changed
until cells were lysed or colonies were scored.
Plasmids, Expression Constructs, and Retroviral Vectors
Full-length ZFP36 and ZFP36L1 cDNAs were generated by RT-PCR per-
formed on total RNA extracted from U937 cells using ZFP36-direct primer
(DP) (5-ATGGATCTGACTGCCATCTACG-3) and ZFP36-reverse primer
(RP) (5-CGGGCAGTCACTTTGTCACT-3) or ZFP36L1-DP (5-GAACGCA-
CAGGATGACCACCA-3) and ZFP36L1-RP (5-CCTACCCTGGCTTAGT-
CATCTGA-3). Ampliﬁcation was carried out using FastStart High Fidelity
PCR System (Roche Applied Science, Penzberg, Germany), and the ampliﬁed
fragments were inserted into the pCR2.1-TOPO T/A cloning vector (Invitro-
gen, Carlsbad, CA) where they were fully sequenced to exclude polymerase-
induced mutations.
ZFP36/ZFP36L1 cDNAs were then EcoRI excised and cloned into an EcoRI-
digested pcDNA3.1 expression vector (Invitrogen) or into an EcoRI-digested
LxIN retroviral vector, resulting in the construction of LZFP36IN and
LZFP36L1IN retroviral vectors.
FlagZFP36/FlagZFP36L1 fragments were RT-PCR ampliﬁed using primers
FlagZFP36-DP (5-ATGGACTACAAAGATGACGACGACAAGGATCTGA-
CTGCCATCTAC-3) and ZFP36-RP or FlagZFP36L1-DP (5-ATGGACTA-
CAAAGATGACGACGACAAGACCACCACCCTCGTGTCT-3) and ZFP36L1-RP
and the ampliﬁed fragments were inserted into the pCR2.1-TOPO T/A cloning
vector, from which they were EcoRI excised and cloned into an EcoRI-
digested pcDNA3.1 vector.
To obtain vectors for in vitro transcription and translation, FlagZFP36/
ZFP36L1 RT-PCR ampliﬁed fragments were inserted into the pEXP5-CT-
TOPO T/A cloning vector (Invitrogen) where they were fully sequenced to
exclude polymerase-induced mutations.
Vegfa and Stat5b ARE-containing 3UTR were ampliﬁed by RT-PCR on
total RNA extracted from U937 cells using Vegfa-3UTR-DP (5-ACA-
GAGAGACAGGGCAGGAT-3) and Vegfa-3UTR-RP (5-GGAATATCTC-
GAAAAACTGCAC-3) or Stat5b-3UTR-DP (5-GATGGCCCCAAAAACCT-
TAT-3) and Stat5b-3UTR-RP (5-TCCCTTCAGAGGAAGGCTTTA-3). The
ampliﬁed fragments were then inserted into the pCR2.1-TOPO T/A cloning
vector and were fully sequenced. The 3UTR fragments were then EcoRI
excised, blunted, and cloned into a SmaI-digested pGL3-Promoter Vector
(Promega, Madison, WI) that had previously been modiﬁed in order to
transfer the multiple cloning region downstream the luciferase reporter gene.
DNA Transfection and Retroviral Infection
Transient transfection of pcDNA3.1-based constructs in Hel cells was ob-
tained using the Amaxa Nucleofector Technology (Lonza Cologne, Cologne,
Germany). Brieﬂy, 1  106 Hel cells were electroporated in 100 l Ingenio
Electroporation Solution (Mirus Bio, Madison, WI) containing 5 go ft h e
desired DNA and using T016 electroporation program. Cells were lysed for
RNA or protein extraction 72 h after electroporation.
The U937 cell line and CD34 HSCs were transduced using LxIN empty
control vector or LZFP36IN/LZFP36L1IN retroviral vectors. Packaging
lines for the LxIN-based constructs were generated by transinfection in the
ecotropic Phoenix and amphotropic GPenvAm12 cells, as previously de-
scribed. Viral titers were assessed by ﬂow cytometry analysis of the expression
percentage of the reporter gene LNGFR upon infection of U937 or CD34
hematopoietic progenitors. Incubation of cells with viral supernatants and puri-
ﬁcation of transduced cells were performed as previously described (Zanocco-
Marani et al., 2006). Transduced U937/CD34 HSCs were lysed for RNA extrac-
tion between 7 and 10 d after transduction, as indicated in ﬁgure legends.
Gene Silencing
Stat5b silencing in Hel cells and in CD34 cells was obtained by using a mix
of two predesigned small interfering RNA (siRNA; Cat. no.: AM16708; siRNA
ID no.: 115945 and 3618; Applied Biosystems, Foster City, CA). Electroporation
was performed using the Amaxa Nucleofector Technology (Lonza Cologne)
according to the manufacturer’s instructions. For each cycle, 5–10 105cells were
electroporated in 100 l Ingenio Electroporation Solution (Mirus Bio) containing
3 g of each siRNA duplex. Every experiment included a negative control
represented by 6 g of a nontargeting siRNA (Dharmacon, Lafayette, CO) in
order to exclude nonspeciﬁc effects of siRNA nucleofection. Hel cells were lysed
for protein or RNA extraction 48 h after electroporation; CD34HSCs were lysed
between 4 and 7 d after electroporation, as indicated in ﬁgure legends.
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Twenty micrograms of total protein extracts obtained by cell lysis in RIPA buffer
or 2 l of in vitro–translated proteins was loaded onto 10% SDS-polyacrylamide
gel and blotted. Membranes were preblocked in blocking solution, 5% milk in
0.1% TBST, for1ha troom temperature and then incubated with a 1:200 dilution
of mouse anti-Stat5b (G-2) monoclonal Ab (MoAb; Santa Cruz Biotechnology,
Santa Cruz, CA), followed by a 1-h incubation at room temperature with goat
anti-mouse IgG conjugated to horseradish peroxidase 1:10,000 (sc-2005, Santa
Cruz Biotechnology). Expression of actin was analyzed with a mouse anti-human
pan-actin MoAb (Sigma-Aldrich, St. Louis, MO) to normalize protein samples.
Detection of in vitro–translated proteins was carried out with anti-ZFP36 poly-
clonal antibody (Abcam, Cambridge, MA; ab36558), anti-ZFP36L1 polyclonal
antibody (Abcam; ab35801), or anti-Flag M2 mouse MoAb (Sigma-Aldrich).
Detection was carried out by using the BM Chemiluminescence Blotting Sub-
strate (Roche Applied Science).
Microarray Data Analysis
Expression proﬁles of CD34 HSCs and CD34-derived erythroblasts,
megakaryoblasts, monoblasts, and myeloblasts were obtained and analyzed
as previously described (Gemelli et al., 2008).
Stat5a, Stat5b, and ZFP36L1 expression levels during in vitro erythroid
differentiation of CD34 hematopoietic progenitor cells were obtained from
the GEO-Proﬁles database (http://www.ncbi.nlm.nih.gov/geo/; GDS2431).
RT-PCR and Real-Time PCR
Total cellular RNA was extracted using the EuroGOLD Total RNA kit (Eu-
roclone) or RNeasy MicroKit (Qiagen, Hilden, Germany). RNA integrity and
concentration was then assessed by the Bio-Analyzer technique (Applied
Biosystems).
For RT-PCR 3 g total RNA were reverse transcribed using M-MLV reverse
transcriptase (Invitrogen), and then expression of speciﬁc genes was assessed by
PCR ampliﬁcation performed using speciﬁc primers: GAPDH-DP (5-GAAGGT-
GAAGGTCGGAGTC-3), GAPDH-RP (5-GAAGGCCATGCCAGTGAGCT-3);
ZFP36L1-DP (5-GAACGCACAGGATGACCACCA-3); ZFP36L1-RP (5-CC-
TACCCTGGCTTAGTCATCTGA-3); Stat5b-DP (5-GATGGCCCCAAAAAC-
CTTAT-3); Stat5b-RP (5-TCCCTTCAGAGGAAGGCTTTA-3); Jak2-DP (5-
GAGCCTATCGGCATGGAATA-3); Jak2-RP (5-TCACCTGAAGGACCACT-
TCC-3); IRF8-DP (5-ATGTGTGACCGGAATGGTG-3); and IRF8-RP (5-CCA-
GACAGAGGGATCCACAT-3). Normalization of the ampliﬁed samples was
obtained by the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) house-
keeping gene.
For quantitative real-time PCR (QRT-PCR) 100 ng total RNA were reverse-
transcribed using the High-Capacity cDNA Archive Kit (Applied Biosystems)
according to the manufacturer’s instructions; QRT-PCR was then performed
with an ABI PRISM 7900 sequence detection system (Applied Biosystems) as
already described (Zanocco-Marani et al., 2006). Primers and probes for the
different genes’ ampliﬁcation were provided by Applied Biosystems; quanti-
tation was performed by amplifying GAPDH mRNA as endogenous control.
Error bars represent SEM calculated on a set of three to four independent
experiments (*p  0.05; **p  0.01).
RNA Electrophoretic Mobility Shift Assays
RNA electrophoretic mobility shift assays (REMSAs) were performed on in
vitro–transcribed/translated FlagZFP36 and FlagZFP36L1 proteins. Such
samples were produced by using the Expressway Cell-Free E. coli Expression
System (Invitrogen) following the manufacturer’s guidelines. Mobility shift
reactions were carried out in gel shift buffer (10 mM HEPES, pH 7.9, 10 mM
KCl, 2 mM MgCl2, 0.5 mM DTT, 10% glycerol, 0.15% NP40) in a total volume
of 20 l. RNA probes were synthesized by Euroﬁns MWG Operon (Ebersberg,
Germany); their sequences are as follows: GMCSF-ARE: 5-UAUUUAUU-
UAUUUAUUUAUUUA-3 (NM_000758, nt from 695 to 716); Stat5b-ARE:
5-AUAGUAAAUUAUUUAUUGGAAGAU-3(NM_012448, nt from 5005 to
5028). Single-stranded RNA probes were 5-end labeled using 32P-ATP
(6000Ci/mmol; PerkinElmer, Waltham, MA) and T4 polynucleotide kinase
(New England Biolabs, Ipswich, MA). The binding reactions contained 1.0 
105 cpm of the indicated labeled probe and 2 l of in vitro–transcribed/
translated protein. Supershifts were determined by an extra 20-minute incuba-
tion in the presence of 1 g Flag M2 mouse MoAb (Sigma-Aldrich). Reactions
were resolved on a nondenaturing 5% polyacrylamide gel. Electrophoresis was
performed at 4°C at 160 V for 3 h.
Luciferase Assays
HEK293 cells were plated at a density of 50,000 cells/well 12 h before
transfection in 24-well plates. Transfections were carried using Lipofectamine
2000 reagent (Invitrogen). In a typical assay, each well received 200 ng of
pGL3-based reporter construct, 200 ng of CMV--galactosidase plasmid
(Clontech Laboratories, Mountain View, CA), and 10–20 ng of pcDNA3.1
FlagZfp36 or pcDNA3.1 FlagZfp36L1, as indicated in ﬁgure legends; the
difference in total DNA transfected was scaled up with pcDNA3.1 empty
vector. After 24–48 h cells were harvested, and cell lysates were assayed for
luciferase and -galactosidase activity (Zappavigna et al., 1994). Each trans-
fection was done in duplicate in the same experiment, and the plotted
luciferase activities represent the average of ﬁve different experiments; error
bars represent SEM (*p  0.05; **p  0.01).
Ribonucleoprotein Complex Immunoprecipitation and
Analysis by RT-PCR
HEK293 cells were cotransfected with pGL3Stat5b-3UTR and pcDNA3.1-
ZFP36L1 plasmids using Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s guidelines. Twenty-four hours after transfection ribo-
nucleoprotein complexes were immunoprecipitated following a protocol de-
scribed in literature (Niranjanakumari et al., 2002). Lysates were immunopre-
cipitated in the presence of protein A Sepharose (CL-4B; GE Healthcare,
Waukesha, WI) previously incubated with anti-ZFP36L1 polyclonal antibody
(Abcam; ab35801), anti-glutathione S-transferase (GST) polyclonal antibody
(Santa Cruz Biotechnology; sc-459), or with no antibody. Immunoprecipitated
mRNAs were retro-transcribed using random hexamers and M-MLV (Molo-
ney murine leukemia virus) reverse transcriptase (Invitrogen). Primers used
for subsequent PCR analysis were DP (5-TCAAAGAGGCGAACTGTGTG-
3) and RP (5-GCTCCTCAGAGGCAGAGAGA-3).
RESULTS
ZFP36L1 Ectopic Expression Down-Regulates Stat5b
Expression and Interferes with Erythroid Differentiation
of Human CD34 Cord Blood–derived Stem/Progenitor
Cells
On the basis of the main hypothesis that ZFP36L1 could be a
negative regulator of erythroid differentiation, we searched the
3UTR regions of mRNAs encoding proteins involved in such
maturation process, in order to ﬁnd AREII sequences. Among
several others not included in the current study, Stat5b ap-
peared to be a suitable candidate, because its 3UTR carries
several canonical and noncanonical AREII sequences. To pre-
liminarily evaluate a possible relation between ZFP36L1 and
Stat5b expression, we overexpressed ZFP36L1 in U937
monoblastic and Hel erythroleukemia cell lines and moni-
tored changes in Stat5b expression. The results are shown in
Figure 1; in particular, panels A and B show the results of
overexpression in U937 cells, whereas panels C and D show
the results of the same experiment performed on Hel cells.
Figure 1A shows an RT-PCR, showing at the mRNA level
that ZFP36L1 overexpression is coupled to a decrease of
Stat5b mRNA. Figure 1B shows the same results analyzed by
QRT-PCR, showing that ZFP36L1 overexpression is also
coupled to the down-regulation of CCL2, a gene previously
described as a target of TTP family proteins (Sauer et al.,
2006). Figure 1C shows a QRT-PCR showing the extent of
ZFP36L1 overexpression obtained in Hel cells. The same
panel includes a Western blot showing Stat5b protein down-
regulation after ZFP36L1 overexpression. To gather further
information on the effect of ZFP36L1 ectopic expression in
Hel cells, we also analyzed by QRT-PCR whether transgene
expression is capable of perturbing the expression of a set of
erythroid differentiation genes. The results are shown in
Figure 1D and show that indeed such perturbation occurs. In
the same panel tumor necrosis factor (TNF)- expression,
previously described as a TTP family target (Carballo et al.,
1997; Johnson and Blackwell, 2002), and -actin were mon-
itored as positive and negative controls.
Consequently to these preliminary experiments, the bio-
logical effect of ZFP36L1 overexpression was assessed in
CD34 human cord blood–derived stem/progenitor cells.
Therefore, CD34 cells were infected with a recombinant
retrovirus allowing ZFP36L1 ectopic expression and then
seeded in methylcellulose to evaluate a possible interference
with differentiation. The results are shown in Figure 1E and
show that, compared with the control (empty vector),
ZFP36L1 ectopic expression determines a drastic decrease in
the formation of erythroid colonies (CFU/BFU-E). In the
same primary cell populations we monitored by QRT-PCR the
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1F) and observed that expression of several among them
(GATA1, LMO2, HbA1, and RhAG) decreases accordingly to
the observed suppression of erythroid differentiation.
ZFP36L1 Directly Binds Stat5b 3-UTR and Thereby Affects
Its Stability. Figure 2A is a REMSA assay showing that an
in vitro–translated, Flag-carrying ZFP36L1 protein is able
to directly bind to radioactively labeled RNA probes cor-
Figure 1. Overexpression of ZFP36L1 negatively regulates Stat5b and impairs erythroid differentiation of CD34 HSCs. (A) RT-PCR
showing the expression levels of ZFP36L1, Stat5b, and Jak2 in U937 cells transduced with empty vector (lane 1) or with ZFP36L1-
overexpressing vector (lane 2); RNAs were extracted 7 d after transduction. (B) Real-time PCR performed on U937 cells transduced with
ZFP36L1-overexpressing vector showing that overexpression of ZFP36L1 down-regulates the expression levels of Stat5b; CCL2 was used as
a positive control. Data are provided in terms of Log2 of relative quantity compared with the expression levels of the same genes in U937
cells transduced with empty vector; error bars, SEM calculated on a set of three independent experiments (*p  0.05). (C) Left, real-time PCR
demonstrating the expression levels obtained in Hel cells via transduction with ZFP36L1-overexpressing vector compared with cells
transduced with empty vector; error bar, SEM calculated on three independent experiments (**p  0.01); RNAs were extracted 72 h after
transduction. Right, Western blot analysis of Stat5b expression in Hel cells transduced with empty vector (lane 1) or with ZFP36L1-expressing
vector (lane 2); cells were lysed 72 h after transduction. (D) Real-time PCR showing that Hel cells overexpressing ZFP36L1 (u) have reduced
levels of Stat5b and of the erythroid markers GATA1, LMO2, RhAG, and HbA1 compared with cells transduced with empty vector ();
TNF- was used as a positive control, and ACTB was used as control housekeeping gene; error bars, SEM calculated on three independent
experiments (*p  0.05; **p  0.01). RNAs were extracted 72 h after transduction. (E) Clonogenic assay performed on CD34 HSCs
transduced with empty vector (left) or overexpressing ZFP36L1 (right); error bars, SEM calculated on four independent experiments (*p 
0.05). (F) Real-time PCR showing that CD34 HSCs overexpressing ZFP36L1 (f) have reduced levels of Stat5b and of the erythroid markers
GATA1, LMO2, RhAG, HbA1 compared with cells transduced with empty vector (); TNF- was used as a positive control and ACTB as
control housekeeping gene (SEM calculated on three experiments; *p  0.05); RNAs were extracted 10 d after transduction.
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(lanes 5–8) and to the AREII regions belonging to GM-CSF
mRNA described in literature (lanes 1–4; Carballo et al.,
2000). The REMSA assay also shows Flag antibody depen-
dent supershift formation (lanes 2 and 6) and cold probe
competition (lanes 3 and 7) for both Stat5b and GM-CSF
probes. Figure 2A also includes a Western blot performed
on the in vitro–translated proteins used in the REMSA
assay showing that both -Flag and -ZFP36L1 antibodies
are capable of binding such proteins. The sequences of the
probes are described in Materials and Methods.
To complete the previous observations, data had to be
gathered on the functional meaning of the bond between
ZFP36L1 and Stat5b mRNA. Therefore, we performed a
luciferase reporter assay, generating luciferase reporter con-
structs (pGL3 based) allowing transcription of a luciferase
mRNA carrying the 3-UTR of Stat5b or, as a control, the
3-UTR of Vegfa, a target gene of TTP family (Ciais et al.,
2004; Bell et al., 2006; Suswam et al., 2008). The results are
shown in Figure 2B and show that coexpression of the
reporter vectors encoding Stat5b or Vegfa 3UTRs with a
vector expressing ZFP36L1 signiﬁcantly decreases the basal
reporter activity, demonstrating that by directly binding the
described mRNAs, ZFP36L1 impairs protein production by
either promoting mRNA degradation or by inhibiting
mRNA translation.
After characterizing the interaction between ZFP36L1 and
Stat5b 3UTR in vitro, next step was to demonstrate that this
interaction could also occur in live cells. For this purpose, we
transfected HEK293 cells with pcDNA3.1-ZFP36L1 and
pGL3-Stat5b-3UTR plasmids and subsequently subjected
them to in vivo cross-linking. ZFP36L1-containing ribonu-
cleoprotein complexes were then immunoprecipitated
from cell lysates using a speciﬁc anti-ZFP36L1 antibody
and the immunoprecipitates were subjected to RT–PCR
ampliﬁcation of the ﬁreﬂy luciferase mRNA. As shown in
Figure 2 panel C, luciferase mRNA was speciﬁcally de-
tected in anti-ZFP36L1 immunoprecipitates and in the
input sample, whereas it was not detectable in the control
immunoprecipitations (-GST Ab, no antibody). These
results demonstrate that the ZFP36L1–Stat5b 3UTR inter-
action occurs not only in reconstituted in vitro systems
but also in living cells.
Comparison between the Effects of Cinnamon Derived Poly-
phenols and ZFP36L1 Expression on Erythroid Differentiation.
To further validate the data collected so far, the effects of
ZFP36L1 ectopic expression were compared with the effects
observed on Hel cells and on CD34 cells after treatment
with cinnamon derived polyphenols, that have been de-
scribed in literature as potent inducers of the genes belong-
ing to the TTP family (Schoene et al., 2005; Cao et al., 2007).
The results are shown in Figure 3. Figure 3A shows by
QRT-PCR the induction of ZFP36L1 obtained after adminis-
tration of cinnamon extracts in Hel cells (24-h treatment with
0.5 g/l cinnamon extracts). Figure 3B shows the subse-
Figure 2. ZFP36L1 binding to AU-rich-elements (ARE) in the
3UTR of Stat5b mRNA confers instability to mRNAs containing
such elements. (A) Left, Western blot demonstrating identity and
integrity of in vitro–translated FlagZFP36L1 protein: immunoblot-
ting was performed with anti-Flag or anti-ZFP36L1 antibody as
indicated. Right, RNA mobility shift assay performed by incubat-
ing in vitro–translated FlagZFP36L1 protein with labeled RNA
probes corresponding to ARE in the 3UTR of GM-CSF mRNA
(used as a positive control, lanes 1–4) or to ARE in the 3UTR of
Stat5b mRNA (lanes 5–8). Probe sequences are: GM-CSF: 5-
UAUUUAUUUAUUUAUUUAUUUA-3; Stat5b: 5-AUAGUAAA-
UUAUUUAUUGGAAGAU-3. Supershifts were obtained by an ad-
ditional incubation with anti-Flag Ab (lanes 2 and 6). Competition
experiments were performed with cold Stat5b probe (lane 3) or with
cold GM-CSF probe (lane 7). Lanes 4 and 8 represent labeled probes
incubated with an in vitro translation reaction mix performed on
empty vector. (B) Luciferase activity assay performed in HEK293
cells transfected with pcDNA3.1 empty expression vector or with
pcDNA3.1 overexpressing FlagZFP36L1 (20 ng) together with pGL3
reporter construct encoding for a luciferase gene fused to the 3UTR
of Vegfa (positive control) or to the 3UTR of Stat5b. Luciferase
activity is represented in terms of fold change; error bars, SEM
calculated on a set of ﬁve independent experiments. (C) Ribonucle-
oprotein complexes immunoprecipitation assay demonstrating that
binding of ZFP36L1 protein to the ARE in the 3UTR of Stat5b mRNA
occurs in vivo: ribonucleoprotein complexes were immunoprecipitated
from lysates of HEK293 cells transfected with pcDNA3.1 ZFP36L1
and pGL3 3UTR Stat5b vectors, RNA was extracted, reverse-tran-
scribed, and ampliﬁed by PCR using primers speciﬁc for Stat5b
3UTR fused to the luciferase gene. Lanes 1 and 2, negative and
positive control respectively, i.e., PCR ampliﬁcation performed on
no template or on RNA extracted from cell lysates before immuno-
precipitation; lane 3, speciﬁc immunoprecipitation obtained with
anti-ZFP36L1 antibody; lanes 4 and 5, control immunoprecipitations
performed with nonspeciﬁc antibody or with no antibody.
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throid related genes, which are quite comparable to those
observed after ZFP36L1 ectopic expression. Figure 3B also
includes, as controls, the expression analysis of the house-
keeping gene -actin, whose expression does not change,
and of CD44, a marker of monocyte differentiation whose
expression increases after cinnamon extract administration.
The up-regulation of CD44 is an event we didn’t further
investigate on, but could be related to the fact that ZFP
family genes are highly expressed in monocytes (ZFP36L1
expression in monoblasts is shown in Figure 4A) and are
induced by phorbol esters, that are capable of triggering
monocyte differentiation. Figure 3C shows cinnamon ex-
tracts -driven ZFP36L1 induction in CD34 cells 24 h after
drug administration (0.25 g/l cinnamon extracts). Figure
3D is a Western blot of the same cells showing the decrease
Figure 3. Treatment with cinnamon extracts up-regulates endogenous expression of ZFP36L1, down-regulates Stat5b levels, and
inhibits erythroid differentiation of CD34 HSCs. (A) Real-time PCR showing up-regulation of ZFP36L1 after treatment of Hel cells
with 0.5 g/l cinnamon extracts for 24 h (SEM calculated on three experiments). (B) Real-time PCR performed on Hel cells treated
with cinnamon extracts showing decreased expression of Stat5b and of the erythroid markers GATA1, LMO2, HbA1, and RhAG; CD44
monocyte differentiation marker expression is increased after treatment with cinnamon extracts; ACTB was used as control house-
keeping gene. Results are provided in terms of Log2 of relative quantity compared with the expression levels of the same genes in
untreated Hel cells; error bars, SEM calculated on a set of three independent experiments (*p  0.05; **p  0.01). (C) Real-time PCR
showing up-regulation of ZFP36L1 after treatment of CD34 HSCs in liquid culture with 0.25 g/l cinnamon extracts for 24 h (SEM
calculated on three experiments). (D) Western blot analysis of Stat5b levels in untreated CD34 HSCs (lane 1) and in the same cells
treated with 0.25 g/l for 48 h (lane 2). (E) Clonogenic assay performed on CD34 HSCs in the absence (left) on in the presence (right)
of cinnamon extracts. Cinnamon extracts were added directly to methylcellulose medium at a concentration of 0.25 g/l (SEM
calculated on three independent experiments; *p  0.05). (F) Real-time PCR showing down-regulation of Stat5b and erythroid markers
in CD34 HSCs treated with 0.25 g/l cinnamon extracts in liquid culture medium for 48 h; CD44 expression is up-regulated after
treatment with cinnamon extracts; ACTB was used as control housekeeping gene. Data are provided in terms of Log2 of relative
quantity compared with the expression levels of the same genes in untreated CD34 HSCs; error bars, SEM calculated on a set of three
independent experiments (*p  0.05; **p  0.01).
ZFP36L1 Down-Regulates Stat5b Expression
Vol. 21, October 1, 2010 3345in Stat5b expression. In parallel to these experiments,
CD34 cells treated with cinnamon extracts were seeded in
methylcellulose. Colony formation was monitored 2 wk af-
ter plating and, as well as in CD34 cells ectopically
expressing ZFP36L1, a statistically signiﬁcant decrease in
erythroid colony formation was observed (Figure 3E).
Figure 3F depicts the QRT-PCR analysis of the expression
of Stat5b and erythroid markers in CD34 cells treated
with cinnamon extracts. Again, the results are in accord
with those observed during ZFP36L1 overexpression. Al-
together, these experiments show that the biological be-
havior of cells ectopically expressing ZFP36L1 is essen-
tially superimposable to that of the same cells treated with
a drug capable of inducing the expression of the genes
belonging to the same family.
Stat5b Gene Silencing Is Sufﬁcient to Impair Erythroid Dif-
ferentiation of Human CD34 Cord Blood–derived Stem/
Progenitor Cells. Because in several contexts Stat5a and
Stat5b act redundantly, we evaluated the expression levels
of the two genes in the different human hematopoietic cell
contexts. Figure 4A is an extract of a microarray analysis
previously performed in our laboratory showing the expres-
sion levels of Stat5a, Stat5b, and ZFP36L1 in human CD34
stem/progenitor cells and in the various myeloid precur-
sors. Figure 4A shows that Stat5a and b are expressed at
comparable levels in all the contexts analyzed with the ex-
ception of erythroblasts, where Stat5a is scarcely represented
compared with Stat5b, and also shows that ZFP36L1 is
scarcely expressed among the different lineages with the
exception of monoblasts. To consolidate this observation, we
monitored the expression of Stat5a, Stat5b, and ZFP36L1 in
a gene expression proﬁle deriving from adult CD34 hema-
topoietic progenitor cells differentiating toward the ery-
throid lineage at various time points up to 11 d, published
on the GEO-Proﬁle database (GDS2431). The results are
shown in Figure 4B and show that during maturation of
human CD34 progenitors toward the erythroid lineage a
down-regulation of Stat5a occurs, whereas high levels of
Stat5b are maintained throughout the process. Again,
ZFP36L1 remains absent along the erythroid differentiation
process. On these grounds, we hypothesized that erythroid
maturation of human CD34 stem/progenitor cells is sus-
tained mainly by Stat5b, rather than Stat5a. Consequently, in
order to evaluate whether the decrease of erythroid differ-
entiation that follows ectopic expression of ZFP36L1 relies
speciﬁcally on the down-regulation of Stat5b, we performed
gene silencing experiments targeting Stat5b in Hel and
CD34 cells. The results of such experiment are described in
Figure 5. Figure 5, A and C, are Western blots showing that
Stat5b expression decreases after siRNA treatment both in
Hel and CD34 cells. Figure 5, B and D, show by QRT-PCR
the decrease of the expression of erythroid markers and the
expression of -actin as a control in Hel and CD34 cells,
respectively, after Stat5b gene silencing. Figure 5E shows
the results of a colony assay performed on CD34 cells
treated with siRNA oligonucleotides targeting Stat5b. The
assay shows a strong decrease in the formation of ery-
throid colonies (CFU/BFU-E) in the cell population where
Stat5b has been down-regulated. This result in particular,
mimics the effect of ZFP36L1 overexpression in the same
cell population.
Transcription Factor IRF8 Is Up-Regulated after ZFP36L1
Ectopic Expression. Because published data suggest that
Stat5 is able to inhibit dendritic development by directly
suppressing transcription factor IRF8 (Esashi et al., 2008), we
evaluated, to further validate our data, whether ZFP36L1-
mediated Stat5b down-regulation indirectly determines a
change in the expression of transcription factor IRF8. The
results of such analysis are shown in Figure 6. Figure 6A
depicts an RT-PCR showing that indeed IRF8 mRNA in-
creases in U937 cells after ZFP36L1 ectopic expression. Fig-
ure 6B shows the same data analyzed by QRT-PCR, whereas
panel C exhibits the changes in IRF8 expression in Hel
cells after treatment with cinnamon extracts. As in the
experiments described in Figure 3, cinnamon extracts in-
duce ZFP36L1 expression; Figure 6C shows that an in-
crease in IRF8 expression is associated with Stat5b down-
regulation. Because the increase of IRF8 expression is
observed both after ZFP36L1 ectopic expression and cin-
namon extracts administration, it is plausible that, in both
cases, this event depends on ZFP36L1-mediated Stat5b
down-regulation.
ZFP36 (TTP) Behaves Comparably to ZFP36L1 and Their
Effect on Stat5b Expression is Cumulative. Because ZFP36
and ZFP36L1 share several targets, we evaluated if ZFP36
also is capable of down-regulating Stat5b and interfering
with hematopoietic differentiation. Figure7Ai saREMSA
Figure 4. Stat5a, Stat5b, and ZFP36L1 expression in hemopoietic
progenitors/precursors and during erythroid differentiation. (A)
Microarray analysis results showing Stat5a, Stat5b, and ZFP36L1
expression levels in primary hemopoietic cell contexts: normal cord
blood CD34 HSCs, CD34-derived erythroblasts, megakaryoblasts,
monoblasts, and myeloblasts. (B) Microarray analysis showing the
expression levels of Stat5a, Stat5b, and ZFP36L1 during in vitro
erythroid differentiation of adult CD34 hematopoietic progenitor
cells at various time points in serum-free medium containing eryth-
ropoietin, IL-3, and stem cell factor (data from GEO Proﬁles data-
base: GDS2431).
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regions of GM-CSF and Stat5b mRNA described in Figure
2A as targets of ZFP36L1. Figure 7A also includes a Western
blot showing that both -Flag and -ZFP36 antibodies are
capable of binding in vitro–translated ZFP36, suggesting
that such protein is folded correctly. Figure 7B is a luciferase
reporter assay performed by cotransfecting a plasmid ex-
pressing ZFP36 and a reporter vector encoding a luciferase
mRNA carrying Stat5b 3-UTR. The results show that ZFP36,
as well as ZFP36L1, determines a decrease of luciferase
activity by binding Stat5b 3-UTR. Next we assessed
whether ZFP36 is also able to interfere with erythroid dif-
ferentiation. Therefore, ZFP36 was ectopically expressed in
CD34 human stem/progenitor cells that successively un-
derwent a methylcellulose colony assay. The results are
described in Figure 7C and show that, compared with the
control population, after 2 wk a decrease of erythroid colo-
nies (CFU/BFU-E) is visible, and it is super imposable to
that observed in CD34 cells overexpressing ZFP36L1. On
these grounds, the hypothesis that the two proteins could act
redundantly was tested. To do so, Hel cells were cotrans-
fected with expression plasmids encoding ZFP36 and
ZFP36L1, and the effect on Stat5b expression was monitored
by Western blot. The results are shown in Figure 7D and
demonstrate that although Stat5b expression decreases after
transfection of one or the other mRNA binding protein
(lanes 2 and 3), their cotransfection (lane 4) is capable of
completely abrogating it. To assess whether the effect on
Stat5b depends on a synergistic or redundant behavior, we
performed another REMSA that is included in the Supple-
mentary Material, showing that ZFP36 and ZFP36L1 bind to
Stat5b 3UTR with equal afﬁnity. Such observation, together
with published data demonstrating that ZFP36 and ZFP36L1
share the domains that recruit deadenylases and therefore
trigger mRNA decay (Lykke-Andersen and Wagner, 2005),
suggests that the two proteins are redundant when coex-
pressed, rather than synergic.
DISCUSSION
Human hematopoietic differentiation is a strictly con-
trolled process in which regulatory events take place at all
the levels of gene expression. Starting from chromatin
conformation moving downstream toward the role of
transcription factors and microRNAs, a wide amount of
data has been gathered so far. With the current study we
suggest a novel mechanism to control hematopoietic dif-
ferentiation based on the activity of mRNA-binding pro-
Figure 5. Stat5b silencing is sufﬁcient to
down-regulate the expression of erythroid
markers and to impair erythroid differentia-
tion of CD34 HSCs. (A) Western blot anal-
ysis showing the down-regulation of Stat5b
obtained in Hel cells transfected with anti-
Stat5b siRNAs (lane 2) compared with cells
transfected with a nontargeting control
siRNA (lane 1); cells were lysed 48 h after
transfection. (B) Real-time PCR performed on
Hel cells transfected with control siRNA ()
or with anti-Stat5b siRNAs (u) demonstrating
the efﬁcacy of Stat5b silencing and the down-
regulation of erythroid markers; ACTB was
used as control housekeeping gene (error
bars, SEM calculated on a set of three exper-
iments; *p  0.05; **p  0.01). RNAs were
extracted 48 h after transfection with siRNAs.
(C) Western blot analysis showing the down-
regulation of Stat5b obtained in CD34 HSCs
transfected with anti-Stat5b siRNAs (lane 2)
compared with cells transfected with a non-
targeting control siRNA (lane 1); cells were
lysed 7 d after transfection. (D) Real-time PCR
performed on CD34 HSCs transfected with
control siRNA () or with anti-Stat5b siRNAs
(f) demonstrating the efﬁcacy of Stat5b si-
lencing and the down-regulation of erythroid
markers; ACTB was used as control house-
keeping gene (error bars, SEM calculated on a
set of three experiments; *p  0.05; **p 
0.01). RNAs were extracted 96 h after trans-
fection with siRNAs. (E) Clonogenic assay
performed on CD34 HSCs transfected with
a nontargeting control siRNA (left) or with
anti-Stat5b siRNAs (right); SEM calculated on
three independent experiments; *p  0.05.
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of the inﬂammatory response (Sandler and Stoecklin,
2008; Schaljo et al., 2009). In our hypothesis, such proteins
act by repressing the development of a speciﬁc blood
lineage, namely the erythroid, rather than by promoting
the differentiation of speciﬁc progenitors and precursors
as classically described in many studies that focus on the
role of transcription factors.
Starting from the analysis of a gene expression database
showing that ZFP36L1 is differentially expressed in the dif-
ferent human blood cell contexts and, particularly, that its
expression is consistently low in the erythroid compared
with the other lineages (data not shown), we hypothesized
that this protein and other members of the same family
could play a role during hematopoiesis. By this study we
demonstrated that ZFP36L1 and ZFP36 inhibit erythroid
development of CD34 human cord blood–derived
stem/progenitor cells by inhibiting proliferation of ery-
throid precursors and suggest that this behavior depends
on ZFP36L1-mediated Stat5b mRNA degradation. More-
over, we demonstrated that ZFP36L1 and ZFP36 share
Stat5b as a common target and are able to directly bind its
mRNA on a canonical AREII sequence located in the
3-UTR. The inhibition of erythroid colonies formation
observed after ZFP36L1 and ZFP36 ectopic expression is
statistically signiﬁcant, and it is coupled to a decrease of
precursors’ proliferation rather than to apoptosis or dif-
ferentiation arrest (see Supplementary Material). To asso-
ciate such observation with the sole down-regulation of
Stat5b was not an obvious step, because this gene is
highly homologous to Stat5a, and in murine erythropoie-
sis the proteins Stat5a and Stat5b are capable to some
degree of substituting each other (Socolovsky et al., 2001).
Therefore, we monitored the expression of Stat5a and Stat5b
in human myeloid cell contexts, at different time points
during human erythroid differentiation and then performed
gene-silencing experiments targeting Stat5b. The expression
analysis revealed that, unlike in murine erythropoiesis, dur-
ing erythroid differentiation of human CD34 stem/pro-
genitor cells, a down-regulation of Stat5a expression occurs,
whereas Stat5b expression persists at high levels (Figure 4).
Accordingly, the gene silencing approach showed that
Stat5b down-regulation is sufﬁcient to impair erythroid mat-
uration. It remains to be elucidated whether the different
expression pattern of Stat5a and Stat5b in human erythro-
poiesis depends on transcriptional or posttranscriptional
events. The presented results show that the idea underneath
is correct, although a more complete hypothesis that rises
from the present study suggests that ZFP36L1, ZFP36, and
possibly other members of the same family could have
among their targets other members of the Stat5b/JAK2 sig-
nal transduction pathway that have not been described in
the experiments presented here.
The relation between ZFP36L1 and Stat5b is also indirectly
described in the experiment (Figure 6) showing that
ZFP36L1 ectopic expression results in the increase of tran-
scription factor IRF8. Such a gene is involved at different
levels in hematopoietic differentiation as a promoter of spe-
ciﬁc myeloid and lymphoid lineages (Qi et al., 2009; Saber-
wal et al., 2009; Wang and Morse, 2009) but not the erythroid
one, it has been described for being negatively regulated by
Stat5 (Esashi et al., 2008) and is capable of acting as a pro-
apoptotic factor (Yang et al., 2007, 2009). The ability of
ZFP36L1 to down-regulate Stat5b, thereby promoting the
expression of the proapoptotic factor IRF8, suggests that this
gene family encodes proteins that in speciﬁc contexts are
able to function as tumor suppressors. Such an observation
is strengthened by a recently published report that shows
that TTP family members are down-regulated in different
tumors (Brennan et al., 2009).
Another relevant aspect of the present work resides in the
fact that drugs capable of inducing the expression of TTP
family genes, such as cinnamon-derived polyphenols, do in
fact down-regulate Stat5b expression and exhibit a very
strong inﬂuence on erythroid maturation of human CD34
stem/progenitor cells. The effect of cinnamon polyphenols is
observed even at low concentrations of drug (0.25 g/l),
Figure 6. Increased levels of ZFP36L1 result in up-regulation of
IRF8 gene. (A) RT-PCR showing increased expression of IRF8 in
U937 cells transduced with ZFP36L1-overexpressing vector (lane
2) compared with cells transduced with empty vector (lane 1);
RNAs were extracted 7 d after transfection. (B) Real-time PCR
showing IRF8 up-regulation after transduction of U937 cells with
ZFP36L1-expressing vector (right); data are provided in terms of
relative quantity compared with cells transduced with empty
vector (left); error bars, SEM calculated on a set of four indepen-
dent experiments; **p  0.01. (C) Real-time PCR showing that
treatment of Hel cells with 0.5 g/l cinnamon extracts for 48 h
results in up-regulation of ZFP36L1, down-regulation of Stat5b,
and up-regulation of IRF8 (SEM calculated on three different
experiments).
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expression of both ZFP36 and ZFP36L1 that, as demon-
strated by the experiment shown in Figure 7D, share the
ability to bind Stat5b mRNA and therefore cooperate in
promoting its degradation.
The present study establishes a relation between the TTP
family of genes and the Stat5b/JAK2 pathway. Alterations
in the genes belonging to such pathway, and precisely the
JAK2 V617F mutation that leads to constitutive signal trans-
duction, underlie chronic myeloproliferative disorders (Bax-
ter et al., 2005; Kralovics et al., 2005; Levine and Gilliland,
2008), such as polycythemia vera (PV), essential thrombocy-
themia (ET), and primary myeloﬁbrosis (PMF). Today there
is considerable optimism that these diseases can be success-
fully treated with tyrosine kinase inhibitors. In fact speciﬁc
inhibitors of JAK2 kinase activity have been designed
(Gozgit et al., 2008; Hexner et al., 2008; Wernig et al., 2008)
and have entered the clinic in Phase I/II trials in PMF and
post-PV/ET myeloﬁbrosis. Given the central role of JAK2
signaling to a myriad of cellular processes, there may be
signiﬁcant toxicities associated with JAK2 inhibition, and
“off-target” inhibition of JAK1, JAK3, or TYK2 might lead to
hematologic, immunologic, and endocrine side effects. Such
toxicities could likely preclude their prolonged use; conse-
quently, it is possible that alternative or synergic therapies
will have to be developed. On these premises and on the
ground of the results presented in this work, we hypothesize
an approach for PV, characterized by an increase in absolute
quantity of erythroid cells, based on the utilization of drugs
that induce TTP gene family expression and that do not
present the toxicity problems suggested above, determined
by JAK2 inhibitors. TTP-inducing drugs would determine
Stat5b down-regulation and would thereby allow decreas-
ing the activity of JAK2-Stat5 pathway without interfering
with the activity of other necessary, unmutated tyrosine
kinases such as JAK1, JAK3, or TYK2 and others. Such an
approach would not likely replace JAK2 inhibitors, but a
combined strategy could possibly be useful to lower the
dosage of tyrosine kinase inhibitors and therefore limit their
toxicity.
Figure 7. ZFP36 behaves similarly to ZFP36L1 in binding to and destabilizing mRNAs spanning Stat5b 3UTR and in inhibiting erythroid
differentiation of CD34 HSCs. (A) Left, Western blot demonstrating identity and integrity of in vitro–translated FlagZFP36 protein:
immunoblotting was performed with anti-Flag or anti-ZFP36 antibody as indicated. Right, RNA mobility shift assay performed by incubating
in vitro–translated FlagZFP36 protein with labeled RNA probes spanning the ARE in the 3UTR of GM-CSF mRNA (used as a positive
control, lanes 1–4) or the ARE in the 3UTR of Stat5b mRNA (lanes 5–8). Supershifts were obtained by an additional incubation with anti-Flag
Ab (lanes 2 and 6). Competition experiments were performed with cold Stat5b probe (lane 3) or with cold GM-CSF probe (lane 7). Lanes 4
and 8 represent labeled probes incubated with an in vitro translation reaction mix performed on empty vector. (B) Luciferase activity assay
performed in HEK293 cells transfected with pcDNA3.1 empty expression vector (left) or with pcDNA3.1 overexpressing FlagZFP36 (10 ng;
right) together with pGL3 reporter construct encoding for a luciferase gene fused to the 3UTR of Stat5b. Luciferase activity is represented
in terms of fold change; error bars, SEM calculated on a set of ﬁve independent experiments. (C) Clonogenic assay performed on CD34
HSCs transduced with empty vector (left) or overexpressing ZFP36 (right); error bars, SEM calculated on four independent experiments (*p 
0.05). (D) Western blot analysis showing Stat5b levels in Hel cells transfected with empty vector (lane 1), with ZFP36-overexpressing vector
(lane 2), with ZFP36L1-overexpressing vector (lane 3), or transfected with both overexpressing vectors (lane 4). Cells were lysed 72 h after
transfection.
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